- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05888831
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Contact Backup
- Name: First line of the email MUST contain the NCT# and Site #.
Study Locations
-
-
Bruxelles-Capitale, Région De
-
Brussels, Bruxelles-Capitale, Région De, Belgium, 1200
- Recruiting
- Cliniques Universitaires Saint-Luc
-
Contact:
- Rachel Galot, Site 0016
- Phone Number: 3227641037
-
-
Oost-Vlaanderen
-
Gent, Oost-Vlaanderen, Belgium, 9000
- Recruiting
- Local Institution - 0017
-
Contact:
- Site 0017
-
-
-
-
Aquitaine
-
Bordeaux, Aquitaine, France, 33076
- Recruiting
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
-
Contact:
- Antoine Italiano, Site 0003
- Phone Number: 33556333333
-
-
Paris
-
Villejuif, Paris, France, 94800
- Recruiting
- Gustave Roussy
-
Contact:
- Antoine Hollebecque, Site 0002
- Phone Number: 33142114385
-
-
Provence-Alpes-Côte-d'Azur
-
Marseille, Provence-Alpes-Côte-d'Azur, France, 13273
- Recruiting
- Institut Paoli-Calmettes
-
Contact:
- Cecile Vicier, Site 0004
- Phone Number: 33491223670
-
-
Rhône-Alpes
-
Lyon CEDEX 08, Rhône-Alpes, France, 69373
- Not yet recruiting
- Centre Leon Berard
-
Contact:
- Armelle Vinceneux, Site 0009
- Phone Number: 33426556833
-
-
-
-
-
Bergamo, Italy, 24127
- Recruiting
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
-
Contact:
- SALVATORE INTAGLIATA, Site 0026
- Phone Number: 0352673687
-
Roma, Italy, 00168
- Recruiting
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
-
Contact:
- Gennaro Daniele, Site 0025
- Phone Number: +39 06 3015 3446
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- Recruiting
- Humanitas
-
Contact:
- Armando Santoro, Site 0023
- Phone Number: 390282244080
-
-
Toscana
-
Siena, Toscana, Italy, 53100
- Not yet recruiting
- Local Institution - 0024
-
Contact:
- Site 0024
-
-
-
-
-
Amsterdam, Netherlands, 1066 CX
- Recruiting
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)
-
Contact:
- Gerrina Ruiter, Site 0030
- Phone Number: 0031205122958
-
Groningen, Netherlands, 9714 CZ
- Recruiting
- University Medical Center Groningen
-
Contact:
- T.Jeroen Hiltermann, Site 0018
- Phone Number: (3150) 361-3532
-
-
-
-
-
Madrid, Spain, 28040
- Recruiting
- Hospital Universitario Fundacion Jimenez Diaz
-
Contact:
- Victor Moreno Garcia, Site 0014
- Phone Number: 615387743
-
Madrid, Spain, 28050
- Recruiting
- Hospital Universitario HM Sanchinarro
-
Contact:
- Emiliano Calvo Aller, Site 0011
- Phone Number: +34620423957
-
-
Andalucía
-
Málaga, Andalucía, Spain, 29010
- Recruiting
- Hospital Universitario Virgen de la Victoria
-
Contact:
- Javier Garcia Corbacho, Site 0015
- Phone Number: 951032250
-
-
Barcelona [Barcelona]
-
Badalona, Barcelona [Barcelona], Spain, 08916
- Recruiting
- Institut Català d'Oncologia (ICO) - Badalona
-
Contact:
- Cinta Hierro Carbo, Site 0013
- Phone Number: 34934978925
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Recruiting
- Clinica Universidad de Navarra
-
Contact:
- Ignacio Melero Bermejo, Site 0012
- Phone Number: 34653574014
-
-
-
-
California
-
Los Angeles, California, United States, 90025
- Recruiting
- The Angeles Clinic and Research Institute - West Los Angeles Office
-
Contact:
- Justin Moyers, Site 0021
- Phone Number: 310-231-2127
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale New Haven Hospital-Smilow Cancer Center
-
Contact:
- Patricia Lo Russo, Site 0007
- Phone Number: 203584-2144
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- John Theurer Cancer Center at Hackensack University Medical Center
-
Contact:
- Martin Gutierrez, Site 0010
- Phone Number: 551-996-5863
-
Hackensack, New Jersey, United States, 07601
- Withdrawn
- Hackensack University Medical Center
-
-
New York
-
Lake Success, New York, United States, 11042
- Recruiting
- R.J. Zuckerberg Cancer Center
-
Contact:
- Richard Carvajal, Site 0022
- Phone Number: 917-886-9377
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy (measurable by Response Evaluation Criteria in Solid Tumors [RECIST] v1.1), and have received, be refractory to, ineligible for, or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant.
- Part 1A may have a solid malignancy of any histology.
- Part 1B is restricted to participants with Non-small cell lung cancer (NSCLC).
- Part 1C is restricted to participants with Triple-negative breast cancer (TNBC).
- Tumor biopsy must be obtained for all participants (unless medically precluded).
Exclusion Criteria:
- History of Grade ≥ 3 toxicity related to prior T-cell agonist or checkpoint inhibitor therapy (eg, anti-cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], or anti-PD- 1/programmed death-ligand 1 [PD-L1] treatment, or any other antibody or drug specifically targeting T-cell co-stimulation or other immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures.
- Current or recent (within 3 months of study intervention administration) gastrointestinal disease or gastrointestinal surgery (eg, intestinal/gastric/colon resection) that could impact the absorption of study intervention.
- Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator.
Other protocol-defined criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation: BMS-986449 monotherapy
|
Specified dose on specified days
|
Experimental: Dose Escalation: BMS-986449 + nivolumab
|
Specified dose on specified days
Other Names:
Specified dose on specified days
|
Experimental: Dose Escalation: BMS-986449 monotherapy pharmacodynamic (PD) cohorts
|
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with Dose-Limiting Toxicities (DLTs)
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
Number of participants with Adverse Events (AEs)
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
Number of participants with Serious Adverse Events (SAEs)
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
Number of participants with AEs leading to discontinuation
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
Number of deaths
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum observed plasma concentration (Cmax)
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
Time of maximum observed concentration within a dosing interval (Tmax)
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
Area under the concentration-time curve within a dosing interval (AUC[TAU])
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA120-1001
- 2023-503484-42 (EudraCT Number)
- U1111-1287-3575 (Registry Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
Clinical Trials on Nivolumab
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...Terminated
-
Bristol-Myers SquibbRecruitingMelanomaSpain, United States, Italy, Chile, Greece, Argentina
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingAdvanced Renal Cell CarcinomaUnited States
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan
-
IRCCS San RaffaeleBristol-Myers SquibbRecruiting